Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest
Eyre TA. et al, (2014), Transfusion, 54, 1231 - 1234
T-cell/histiocyte-rich large B-cell lymphoma - transformation of Nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow
Eyre TA. et al, (2014), European Journal of Haematology, 92, 550 - 551
The mRNA-binding protein LARP1 is a pro-survival factor that promotes tumourigenicity and chemotherapy resistance in ovarian cancer
Hopkins TG. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, S26 - S26
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies
Eyre TA. et al, (2014), British Journal of Haematology
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
Lorigan P. et al, (2014), Br J Dermatol, 170, 87 - 95
Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Reilly JT. et al, (2014), British Journal of Haematology, 167, 418 - 420
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
Fotopoulou C. et al, (2014), Ann Oncol, 25, 160 - 165
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley L. et al, (2013), Cancer Chemother Pharmacol, 72, 1343 - 1352
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours
Horsley L. et al, (2013), Cancer Chemotherapy and Pharmacology, 72, 1343 - 1352
Extranodal NK/T cell lymphoma, nasal type, presenting with meningeal infiltration in a Caucasian female
Hildyard C. et al, (2013), British Journal of Haematology, 163
The Influence Of KIR Haplotype In ITP Incidence, Treatment Response and Bleeding Symptoms
Psaila B. et al, (2013), BLOOD, 122
Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells.
Böiers C. et al, (2013), Cell Stem Cell, 13, 535 - 548
Classical Hodgkin's lymphoma: past, present and future perspectives.
Eyre TA. et al, (2013), Br J Hosp Med (Lond), 74, 612 - 618
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
Shapiro G. et al, (2013), MOLECULAR CANCER THERAPEUTICS, 12
Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.
Sanjuan-Pla A. et al, (2013), Nature, 502, 232 - 236
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
New M. et al, (2013), Cell Death Differ, 20, 1306 - 1316
Current treatment and future prospects for peripheral T-cell lymphoma.
Eyre TA. and Collins GP., (2013), Drugs Today (Barc), 49, 631 - 646
DNA repair proteins XPF and MUS81 are predictive biomarkers for neoadjuvant oxaliplatin-fluorouracil chemotherapy in patients with operable oesophageal adenocarcinoma
MacGregor T. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 56 - 56
Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C. et al, (2013), Expert Rev Hematol, 6, 511 - 523
Results of restaging oesophageal and junctional cancer after neoadjuvant chemotherapy with PET-CT alone
Findlay J. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 46 - 46